March 12, 2021
Amring Pharmaceuticals Inc. announced an agreement with Amzell B.V. for the commercial rights to a leading clinical-stage program that will bring critical and accessible therapy for patients in need.
Recent Posts
- Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
- Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board
- Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
- Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair
- Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
Archives
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- June 2023
- July 2022
- June 2022
- February 2022
- December 2021
- November 2021
- October 2021
- August 2021
- March 2021
- December 2020
- August 2020
- June 2019
- January 2019
- July 2018
- June 2017
- March 2017
- April 2016
- March 2016
- January 2016
- December 2015
- June 2015
Recent Comments